#aacr 2024

[pathologylab]

Exciting Day 1 at #AACR2024! Here's a sneak peek of the inspiring discussions from the #American Association for Cancer Research.

Huge thanks to all the scientists and doctors who stopped by #G2M's booth #853 as our team had insightful conversations regarding our highly innovative and groundbreaking product portfolio which is shaping the future of #cancer diagnosis and treatment. Make sure to stop by our booth to explore the latest innovations in oncology RT-PCR and #NGS clinical panels and point-of-care #solutions.

#genes2me #CancerResearch #rtpcr #Oncology #SanDiegoConference #pcr #ivd #California #diagnosis #innovative #products

[esseha]

Mise en garde de l'Association américaine pour la recherche sur le cancer

Le dernier rapport de l’Association américaine pour la recherche sur le cancer (AACR), publié le 7 septembre 2024 et relayé par le Daily Mail, souligne une réalité inquiétante : le cancer touche de plus en plus d’adolescents et de jeunes adultes. Les chercheurs ont identifié six facteurs clés qui contribuent à ce phénomène. Tout d’abord, une alimentation déséquilibrée se révèle particulièrement…

[jcnnewswire]

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

http://dlvr.it/T5JYbB

[thxnews]

Innovent Revolutionizes Cancer Care at AACR

At the 2024 AACR Meeting, Innovent Biologics will unveil groundbreaking preclinical data on novel bispecific antibodies and ADCs, heralding a significant advancement in oncology and promising new, effective cancer treatments. This represents a pivotal moment in the fight against cancer.  

IBI3001: The Vanguard of Innovent's Arsenal

At the heart of Innovent's presentation is IBI3001, a novel anti-cancer drug that embodies the cutting-edge of therapeutic design. This site-specific glycan-conjugated B7-H3/EGFR bispecific ADC aims at tackling multiple solid tumors with unprecedented precision.   Dr. Kaijie He, Innovent's Vice President,  stated: “We are pleased that the pre-clinical studies of our novel anti-cancer drugs are accepted for Late-Breaking Research poster presentation at the 2024 AACR conference. This is the result of dedicated work from scientists at Innovent Academy with the aim to tackle cancers with innovative drugs that are more effective and safer. With careful design and optimization, our molecules can achieve favorable therapeutic windows of 40 to more than 200 times. We look forward to their performance in clinical settings and hope that these innovations can eventually benefit cancer patients.”  

A Spectrum of Innovation

In addition to IBI3001, Innovent is gearing up to reveal preclinical findings on a TROP2-targeted immune stimulating antibody conjugate (ISAC). This novel molecule demonstrates potent anti-tumoral activity coupled with an acceptable safety profile, promising a brighter future for cancer patients. Dr. He is optimistic about the therapeutic windows these innovations could open, with favorable ratios ranging from 40 to over 200 times, underscoring their potential efficacy in clinical settings.   The Bigger Picture: Confronting Cancer Cancer's toll on global health remains staggering, with millions of lives claimed annually. It's a battle fought on multiple fronts: genetic predispositions, lifestyle factors, and the dire need for effective treatments. Herein lies the importance of Innovent's work, aiming not only to extend the frontier of cancer treatment but also to offer hope to those embroiled in this fight. The company's contributions to early detection and treatment could significantly alter the landscape of cancer care, emphasizing the importance of continuous innovation in the medical field.  

Toward a Future Without Cancer

Innovent Biologics' presentation at the 2024 AACR Annual Meeting stands as a testament to the relentless pursuit of medical advancement. As we edge closer to unraveling the complexities of cancer, the contributions of companies like Innovent illuminate the path forward, promising a future where cancer's grip on humanity is significantly weakened.   Sources: THX News & Innovent Biologics, Inc.. Read the full article

[vietnamstar]

Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting

BEIJING, April 4, 2024 /PRNewswire/ — Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microenvironment targeting CD98-directed ADC, at the American Association for Cancer Research (AACR) Annual…

[newsheadlinesnow]

PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024

http://dlvr.it/T4jdTK

[wavenyan]

アルプスあづみのセンチュリーライド2024大会公式ウエア

AACRことアルプスあづみのセンチュリーライド2024大会公式ウエアが販売中だよ！ https://aacr.jp/original_goods.html

●ニャンさんグッズWEB受注中！→http://urx.blue/NTgn ●ウエイブニャン公式サイト→http://wavenyan.com/ ●ウエイブニャンLINEスタンプ発売中！→http://urx.blue/NTgo ●ピクシブ→https://pixiv.me/user_mxcr8474 ●インスタグラム→https://www.instagram.com/wavenyan/

#アルプスあづみのセンチュリーライド #AACR #桜のAACR #緑のAACR #ネコ #ねこ #猫 #可愛い #かわいい #カワイイ #キャラクター #イラスト #WAVEONE #ウエイブワン #ウエイブニャン #roadrace #cycle #cute #cycling #cat #cyclesports #cyclejersey #goneriding #instacycling

[delectablywaywardbeard-blog]

Premio Pezcoller-Aacr 2024 a de Lange per ricerche sui tumori

È la professoressa Titia de Lange, scienziata di origine olandese che dirige il centro di ricerca sul cancro presso la Rockefeller University di New York, la vincitrice del Premio Pezcoller-Aacr 2024. Si tratta della quarta donna a vincere il riconoscimento che premia la ricerca contro i tumori. La nomina è stata comunicata in conferenza stampa dal presidente della fondazione Pezcoller,…

[pathologylab]

Discover the cutting-edge world of #GeneticTesting with #G2M! Our portfolio boasts over 27 Next-Generation #Sequencing (NGS) Panels, covering a wide spectrum of #genetic and somatic disorders, including cancer. These #panels are compatible with the major sequencing platforms available in the market. All our panels are complemented with the data #analysis and reporting #software - CliSeq Interpreter. 👉 To know more about the NGS Solutions, join us at #AACR 2024, San Diego, California from 07-10th Apr'24 (Booth #853). Our team is ready to offer insights, answer questions, and explore collaborations. Click here to book your meeting slot https://www.genes2me.com/upcoming-events For more details, Call us at +91-8800821778 or drop us an email at social@genes2me.com #g2m #ngs #software #solutions #conference #meeting #testing #diego #california #GENES2ME #cliseq #nextgenerationsequencing #rtpcr #pcr